Relonova in the relief of migraine episodes
DOI: 10.32364/2587-6821-2024-8-10-3
E.G. Filatova1,2, N.V. Latysheva1,2, N.B. Kadymova2, A.V. Berdnikova1,2
1I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
2A. Vein Clinic of Headache and Autonomic Disorders, Moscow, Russian Federation
Aim: to assess the efficacy and safety of the new Russian generic rizatriptan 10 mg tablet in alleviating migraine episodes in a real clinical practice.
Patients and Methods: an open-label comparative study was conducted involving 30 patients diagnosed with migraine. Each participant was instructed to treat four migraine episodes (totaling 120 seizures) using rizatriptan 10 mg, administered at the onset of a headache, and to maintain self-monitoring diaries. If the headache recurred after initial relief, but not sooner than two hours after the first dose, a second tablet was advised. In cases where rizatriptan provided insufficient analgesic effect, the use of common analgesics was permitted. The study focused on evaluating both the drug's efficacy and safety profiles.
Results: a total of 102 migraine episodes were successfully treated, while some patients opted out due to perceived insufficient efficacy. Pain relief or reduction was reported in 86% of episodes two hours post-dose, and in 87% after 24 hours. Complete pain absence was noted in 45% of episodes two hours after drug administration, and in 68% after 24 hours. A response rate was observed in 63% of participants. Non-responders, identified as those showing no improvement in at least three episodes, exhibited more severe associated symptoms such as photophobia and phonophobia, and a marked increase in headache intensity following physical activity. Mild adverse events were reported in 25% of the episodes, resolving spontaneously without the need for additional therapy.
Conclusion: the Russian generic rizatriptan 10 mg tablet was demonstrated to be an effective and safe treatment option for mitigating migraine episodes.
Keywords:hadache, migraine, triptans, relief of migraine episode, rizatriptan, real clinical practice.
For citation: Filatova E.G., Latysheva N.V., Kadymova N.B., Berdnikova A.V. Relonova in the relief of migraine episodes. Russian Medical Inquiry. 2024;8(10):560–567 (in Russ.). DOI: 10.32364/2587-6821-2024-8-10-3
About the authors:
Elena G. Filatova — Dr. Sc. (Med.), Professor of the Department of Nervous Diseases of the Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University); 8, build. 2, Trubetskaya str., Moscow, 119991, Russian Federation; neurologist at the A. Vein Clinic of Headache and Autonomic Disorders; 10B, Staropetrovsky passage, Moscow, 125130, Russian Federation; ORCID iD 0000-0001-9978-4180
Nina V. Latysheva — Dr. Sc. (Med.), Professor of the Department of Nervous Diseases of the Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University); 8, build. 2, Trubetskaya str., Moscow, 119991, Russian Federation; neurologist at the A. Vein Clinic of Headache and Autonomic Disorders; 10B, Staropetrovsky passage, Moscow, 125130, Russian Federation; ORCID iD 0000-0001-9600-5540
Natalia B. Kadymova — C. Sc. (Med.), neurologist at the A. Vein Clinic of Headache and Autonomic Disorders; 10B, Staropetrovsky passage, Moscow, 125130, Russian Federation; ORCID iD 0009-0005-8965-9980
Anna V. Berdnikova — Assistant Professor of the Department of Nervous Diseases of the Institute of Professional Education, I.M. Sechenov First Moscow State Medical University (Sechenov University); 8, build. 2, Trubetskaya str., Moscow, 119991, Russian Federation; neurologist at the A. Vein Clinic of Headache and Autonomic Disorders; 10B, Staropetrovsky passage, Moscow, 125130, Russian Federation; ORCID iD 0000-0002-4447-2152
Contact information: Elena G. Filatova, e-mail: eg-filatova@mail.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 06.08.2024.
Revised 29.08.2024.
Accepted 23.09.2024.
2. Азимова Ю.Э., Амелин А.В., Алферова В.В. и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1‑3):4–36. DOI: 10.17116/jnevro20221220134Azimova Y.E., Amelin A.V., Alferova V.V. et al. Clinical guidelines "Migraine". S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1‑3):4–36 (in Russ.). DOI: 10.17116/jnevro20221220134
3. Dahlof C., Lines C. Rizatriptan: a new 5-HT1B/1D receptor agonist for the treatment of migraine. Expert Opin Investig Drugs. 1999;8(5):671–685. DOI: 10.1517/13543784.8.5.671
4. Diener H.C., Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001;10(10):1831–1845. DOI: 10.1517/13543784.10.10.1831
5. Ferrari A., Pinetti D., Bertolini A. et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol. 2008;64(5):489–495. DOI: 10.1007/s00228-007-0443-9
6. Yates R.A., Tateno M., Nairn K. et al. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2002;58(4):247–252. DOI: 10.1007/s00228-002-0461-6
7. Géraud G., Keywood C., Senard J.M. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376–388. DOI: 10.1046/j.1526-4610.2003.03073.x
8. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56. DOI: 10.1002/ana.410330109
9. Cady R.K., Vause C.V., Ho T.W. et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009;49(9):1258–1266. DOI: 10.1111/j.1526-4610.2009.01523.x
10. Viana M., Genazzani A.A., Terrazzino S. et al. Triptan nonresponders: do they exist and who are they? Cephalalgia. 2013;33(11):891–896. DOI: 10.1177/0333102413480756
11. Ferrari A., Tiraferri I., Neri L., Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain. 2011;12(1):5–12. DOI: 10.1007/s10194-010-0258-4
12. Хохлов А.Л., Лейкин З.Н. Сравнительное клиническое исследование фармакокинетики и биоэквивалентности препаратов ризатриптана Релонова и Максалт. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(8):68–74. DOI: 10.17116/jnevro202312308168Khokhlov A.L., Leykin Z.N. Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8):68–74 (in Russ.). DOI: 10.17116/jnevro202312308168
13. Sacco S., Lampl C., Amin F.M. et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):133. DOI: 10.1186/s10194-022-01502-z
14. Филатова Е.Г., Осипова В.В., Табеева Г.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, психиатрия, психосоматика. 2020;12(4):4–14. DOI: 10.14412/2074-2711-2020-4-4-14Filatova E.G., Osipova V.V., Tabeeva G.R. et al. Diagnosis and treatment of migraine: Russian experts' recommendations. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4–14 (in Russ.). DOI: 10.14412/2074-2711-2020-4-4-14
15. Cameron C., Kelly S., Hsieh S.C. et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55 Suppl 4:221–235. DOI: 10.1111/head.12601
16. Tfelt-Hansen P., Teall J., Rodriguez F. et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache. 1998;38(10):748–755. DOI: 10.1046/j.1526-4610.1998.3810748.x
17. Pascual J., Vega P., Diener H.C. et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia. 2000;20(5):455–461. DOI: 10.1046/j.1468-2982.2000.00069.x
18. Tfelt-Hansen P., De Vries P., Saxena P.R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259–1287. DOI: 10.2165/00003495-200060060-00003
19. Wilkins A.J., Haigh S.M., Mahroo O.A., Plant G.T. Photophobia in migraine: A symptom cluster? Cephalalgia. 2021;41(11-12):1240–1248. DOI: 10.1177/03331024211014633
20. Villar-Martinez M.D., Goadsby P.J. Pathophysiology and Therapy of Associated Features of Migraine. Cells. 2022;11(17):2767. DOI: 10.3390/cells11172767
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать